| Literature DB >> 32915312 |
Ken Möhwald1,2, Max Wuehr3, Fabian Schenkel3, Katharina Feil3,4, Michael Strupp3,4, Roman Schniepp3,4.
Abstract
OBJECTIVE: To uncover possible impairments of walking and dynamic postural stability in patients with primary orthostatic tremor (OT).Entities:
Keywords: Gait ataxia; Gait disorder; Orthostatic tremor; Walking stability
Mesh:
Year: 2020 PMID: 32915312 PMCID: PMC7718181 DOI: 10.1007/s00415-020-10177-y
Source DB: PubMed Journal: J Neurol ISSN: 0340-5354 Impact factor: 4.849
Patient characteristics including neurological findings and medication
| Patient | Gender | Age (years) | Tremor frequency (Hz) | Duration (years) | Tremor treatment | Cerebellar signs | Further neurological findings | ABC | FES-I | FGA | Falls |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | f | 54 | 17.0 | 7 | Baclofen 30 mg/day | 3 | 1, 6, 7 | 33 | 39 | 18a | No |
| 2 | f | 73 | 16.5 | 26 | Primidone 125 mg/day | 1 | 1, 5, 6 | 22 | 42 | 19 | Yes |
| 3 | m | 77 | 17.5 | 23 | 1, 2, 3 | 1, 5, 6, horizontal periodic alternating nystagmus | 43 | 43 | 20 | No | |
| 4 | m | 72 | 13.5 | 23 | 3 | 1, 2, 4, 5, 6 | 15 | 51 | 15a | No | |
| 5 | f | 62 | 16.0 | 15 | 2, 3 | 1, 5, 6, 7 | 49 | 40 | 17a | Yes | |
| 6c | m | 72 | 14.5 | 16 | Clonazepam 0.5 mg/day | 1, 2, 3 | 1, 2, 5, 6 | 53 | 28 | 18 | Yes |
| 7 | f | 72 | 17.0 | 8 | Gabapentin 1200 mg/day + Primidone 375 mg/day | 1, 2, 3 | 1, 2, 4, 5, 6 | 7 | 57 | b | Yes |
| 8 | f | 63 | 14.0 | 15 | Pregabalin 150 mg/day | 1, 2 | 1, 4, 5, 7 | 59 | 21 | 25 | No |
| 9 | f | 69 | 15.0 | 19 | Gabapentin 300 mg/day | 1, 2, 3 | 1, 4, 5, 6, head tremor | 37 | 37 | 16a | No |
| 10 | m | 72 | 17.0 | 10 | 2 | 1, 4, 5 | 87 | 25 | 26 | No | |
| 11c | f | 78 | 14.0 | 18 | Gabapentin 900 mg/day | 1, 2, 3 | 1, 2, 5, 6 | 62 | 46 | b | Yes |
| 12 | f | 72 | 16.0 | 20 | 2 | 1, 5, 6, pronation forearm holding test | 24 | 48 | 18 | No | |
| 13 | m | 77 | 14.5 | 18 | Gabapentin 2000 mg/day | 1, 2 | 1, 2, 5, 6 | 75 | 28 | 12a | No |
| 14 | m | 73 | 11.5 | 8 | 2, 3 | 1, 5, 6, muscle atrophy of lower limb (right > left) | 65 | 28 | 19 | No | |
| 15 | m | 71 | 13.0 | 1 | 1, 2, 3, 4 | 1, 2, 5, 6, 7 | 24 | 24 | 20 | No | |
| 16 | f | 72 | 11.0 | 5 | Propranolol 120 mg/day | 1, 4 | 1, 6, pronation forearm holding test | 58 | 30 | 17 | Yes |
| 17 | m | 73 | 14.0 | 11 | 1, 2, 3 | 1, 2 (right), 3, 4, 5, 6 | 28 | 49 | 9a | No | |
| 18 | f | 67 | 15.5 | 9 | Clonazepam 0.3 mg/day | 1, 2 | 1, 2, 4, 5, 6, drooping mouth on right side | 81 | 25 | b | No |
Cerebellar signs: 1 = cerebellar ocular motor disorder, 2 = upper limb dysmetria, dysdiadochokinesia or intention tremor (uni- or bilateral), 3 = lower limb dysmetria (uni- or bilateral), 4 = dysarthria
further neurological findings: 1 = saccadic smooth pursuit, 2 = pathological head impulse test (bilateral, if unilateral, left or right side indicated), 3 = rigidity, 4 = postural tremor, 5 = impaired ankle reflexes and/or reduced vibration sense, 6 = positive Romberg’s sign, 7 = deviation of the subjective visual vertical (SVV)
ABC: Activities-specific Balance Confidence Scale (ranging from 0 to 100%, > 80 high level of physical function; 50–80 moderate level of physical function; < 50 low level of physical function); FES-I: Falls Efficacy Scale-International (total score range from 16, i.e., no concern about falling, to 64, i.e., severe concern about falling); FGA: Functional Gait Assessment (ranging from 0 to 30, with 30 being the best possible score)
f female, m male
aFGA score below the age-referenced norm [10]
bFGA testing aborted due to permanent instability
cSiblings
Fig. 1Overview of walking impairments in patients with orthostatic tremor. Comparison of walking performance in patients with orthostatic tremor vs. healthy controls across different speed, sensory, and dual-task conditions (rows) and with respect to different gait parameters (columns, grouped by four functional gait domains: pace, phase, posture, and variability). Numbers within each tile represent the mean percentage difference of patients’ walking performance compared to healthy controls. SLength stride length, STime stride time, Dsupp percentage of double support phase, Swing percentage of swing phase, BoS base of support, CV coefficient of variation, SS slow walking speed, PS preferred walking speed, MS maximal walking speed, HR head reclination, EC eyes closed, DTC cognitive dual task, DTM motor dual task
Fig. 2Modulation of gait characteristics across different walking conditions. Alterations in a base of support and b stride time CV in patients with OT (red) and healthy controls (grey) in dependence on the walking speed (SS, PS, MS) as well as during walking with EC or DTC. *Significant difference. CV coefficient of variation, SS slow walking speed, PS preferred walking speed, MS maximal walking speed, EC eyes closed, DTC cognitive dual task